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Tumors are capable of coopting hematopoietic cells to create a suitable microenvironment
to support malignant growth. Here, we have demonstrated that upregulation of kinase insert
domain receptor (KDR), also known as VEGFR2, in a myeloid cell sublineage is necessary
for malignant progression of gliomas in transgenic murine models and is associated with
high-grade tumors in patients. KDR expression increased in myeloid cells as myeloid-
derived suppressor cells (MDSCs) accumulated, which was associated with the
transformation and progression of low-grade fibrillary astrocytoma to high-grade anaplastic
gliomas. KDR deficiency in murine BM-derived cells (BMDCs) suppressed the
differentiation of myeloid lineages and reduced granulocytic/monocytic populations. The
depletion of myeloid-derived KDR compromised its proangiogenic function, which inhibited
the angiogenic switch necessary for malignant progression of low-grade to high-grade
tumors. We also identified inhibitor of DNA binding protein 2 (ID2) as a key upstream
regulator of KDR activation during myeloid differentiation. Deficiency of ID2 in BMDCs led
to downregulation of KDR, suppression of proangiogenic myeloid cells, and prevention of
low-grade to high-grade transition. Tumor-secreted TGF-b and granulocyte-macrophage
CSF (GM-CSF) enhanced the KDR/ID2 signaling axis in BMDCs. Our results suggest that
modulation of KDR/ID2 signaling may restrict tumor-associated myeloid cells and could
potentially be a therapeutic strategy for preventing transformation of premalignant gliomas.
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Introduction
The emerging role of BM-derived cells (BMDCs), including 
myeloid-derived suppressor cells (MDSCs), dendritic cells, neu-
trophils, and macrophages (1–6), has become a focus of recent 
research in malignant progression. Numerous studies have 
demonstrated that tumors directly influence hematopoietic cells 
toward protumoral phenotypes via complex molecular signaling 
pathways (4, 7). Interactions with stromal components or tumor 
cells allow BMDCs to promote angiogenesis, resistance, and inva-
sion in various types of cancers, including brain tumors (5, 8).
Gliomas represent the most prevalent malignant brain tumors 
and are classified by WHO as grade I, II, III, or IV. WHO grades are 
uniquely defined by the presence of specific pathological features, 
including cell proliferation, necrosis, and the extent of angiogenesis 
(9). In comparison with their low-grade (grade II) counterparts, high-
grade gliomas (grade III/IV) are characterized by microvascular pro-
liferation and necrosis (9–11). While a percentage of high-grade glio-
mas develop de novo, these tumors may also result from malignant 
transformation of lower grade tumor variants (9, 10, 12). Patients with 
low-grade gliomas have an increased chance of cure using aggressive 
therapies, including total surgical resection and chemotherapy, and 
may live many progression-free years with residual tumor that cannot 
safely be removed through gross total resection (10, 12, 13). Once low-
grade tumors undergo malignant transformation to a higher grade, 
however, prognosis often mirrors de novo diagnosis of high-grade 
gliomas and often leads to poor clinical outcomes (14, 15).
A more thorough understanding of the tumor microenviron-
ment, particularly the role of BMDCs towards malignant glioma 
transformation, has substantial biological and clinical relevance inso-
far as arresting malignant progression has implications for long-term 
disease survival. In this study, we found that kinase insert domain 
receptor (KDR), also known as VEGFR2, is responsible for driving 
differentiation of hematopoietic progenitor cells (HPCs) into pro-
tumoral MDSCs. Through enhanced signaling of hematopoietic- 
derived inhibitor of DNA binding protein 2 (ID2), a member of 
the inhibitor of DNA binding proteins class, primary tumors direct 
myeloid progenitors to develop into tumor-associated BMDCs via 
upregulation of KDR and, in turn, stimulate the aggressive proangio-
genic phenotype of gliomas.
Results
Intracellular KDR in glioma-associated myeloid cells. KDR has been 
identified in both endothelial and endothelial progenitor cells 
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grade IV tumors. Use of the RCAS/TVA model allowed monitoring 
of KDR expression throughout both the formation and malignant 
progression of gliomas. During tumor progression from a low-
grade stage (~week 5) to a high-grade stage (~week 8), the popula-
tion of CD11b+KDRGFP+ cells within the peripheral blood increased 
5-fold (Figure 1, A and B). During this transition, tumor-associated 
macrophages within tumor tissue were also increased 5-fold (Sup-
plemental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/JCI86443DS1), mirroring the 
elevated populations of MDSCs (Supplemental Figure 1B). Within 
the CD11b+KDRGFP+ population in peripheral blood, the majority of 
cells phenotypically resemble MDSCs (Ly6G+ or Ly6C+). Approxi-
mately 60% of CD11b+KDRGFP+ cells had monocytic features ver-
sus 15% of the CD11b+KDRGFP– cells (Ly6C+; Figure 1, C and D). 
Among BM progenitor cells, more than 80% of Lin– KDRGFP+ cells 
were hematopoietic stem cells (HSCs) (Lin–/c-Kit+/Sca-1+) or HPCs 
(Lin–/c-Kit+/Sca-1–) (Supplemental Figure 1, C and D).
within various models of tumor malignancy (2, 16–18). Recently, 
KDR was found to be expressed by BM-derived plasmacytoid den-
dritic cells (19), suggesting it may have a broader impact on tumor 
microenvironment than previously thought. To study the expres-
sion pattern of KDR in gliomas at different stages, we utilized 
KdrGFP mice, with GFP knocked into the Kdr locus, crossbred with 
Nestin-tva Ink4a/Arf–/– Ptenfl/fl mice. The replication-competent avi-
an sarcoma-leukosis virus (ASLV) long terminal repeat (LTR) with 
a splice acceptor/tumor virus A (RCAS/TVA) system was used to 
induce PDGF/protein kinase B–driven (PDGF/Akt-driven) gliomas 
from neural progenitor cells in postnatal mice (20, 21). These mice 
develop low-grade gliomas that invariably progress to higher grades 
over a reproducible 12-week time course. Initially, at approximately 
week 5, the tumors mimic fibrillary astrocytomas, which are equiv-
alent to the low-grade human grade II tumors but subsequently 
progress to anaplastic astrocytomas (grade III) and, by weeks 8–12, 
progress to malignant gliomas akin to human glioblastoma or WHO 
Figure 1. Elevated KDR expression in myeloid cells is associated with malignant murine gliomas. (A) Representative flow cytometry graphs of CD11b and 
GFP in peripheral blood of KDRGFP mice bearing gliomas. Astrocytic tumors were generated by RCAS/TVA-mediated overexpression of PDGF as described in 
Methods. Low-grade gliomas were observed by week 5 and high grade by weeks 7–8. Controls (CTL) were mice bearing an intact Kdr locus without GFP knockin. 
(B) Quantification of CD11b+KDRGFP+ cell frequency in peripheral blood of RCAS/TVA tumor mice at low-grade and high-grade stages. ***P < 0.001, Student’s t 
test. LEU, Leukocytes. (C) Further characterization of murine CD11b+KDRGFP+ cells in peripheral blood by Ly6C and Ly6G staining. (D) Quantification of Ly6G+ and 
Ly6C+ frequency out of total CD11b+ cells in the CD11b+KDRGFP+ and CD11b+KDRGFP– populations in peripheral blood at high-grade stage. **P < 0.01, for Ly6Chi cells, 
Student’s t test. (E) CFU assays were performed on Lin–KDRGFP+ hematopoietic cells from BM, and macrophage (M) colonies and macrophage/granulocyte (GM) 
colonies, but not granulocyte (G) colonies, were observed. Quantification of various colony types formed from lineage-negative KDRGFP– or KDRGFP+ cells.  
***P < 0.001, in granulocytes, Student’s t test. (F) Gene expression (quantitative RT-PCR) of various markers, including Kdr in in vitro–cultured BM Lin– cells 
exposed to GL261-conditioned medium at different time points. *P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA. Data are shown as mean ± SD.
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pared with samples from low-grade glioma patients (Figure 2, A 
and B). Specifically, the levels of CD11b+KDR+ cells were higher 
in patients with grade III or IV tumors than they were in patients 
with grade I tumors and healthy controls (Figure 2B). Among all 
patients, 2 grade III patients and 4 grade IV patients had received 
chemotherapy, 7 grade IV patients had received steroids, and none 
had received radiotherapy or targeted therapy by the time of sam-
ple collection. Importantly, the elevated levels of CD11b+KDR+ 
cells were not induced by treatments that patients had received 
(Supplemental Figure 2, A and B).
Perhaps the most striking of our findings was the apparent 
delineation of 2 distinct populations of patients, each with patho-
logically defined grade II astrocytoma. We divided patients with 
grade II astrocytoma into 2 subgroups, those with high versus those 
with low CD11b+KDR+ values (cut-off of 1.0%). The clinical course 
and medical histories of the patients were closely followed over 12 
months. Disease progression in patients with grade II glioma was 
assessed by MRI and subsequent histological diagnoses of grade 
III or IV glioma (Supplemental Figure 2C). The progression-free 
survival of our cohort of grade II patients is shown in Figure 2C. 
Patients with an elevated percentage of CD11b+KDR+ (KDRHi) 
myeloid cells presented with a significantly higher likelihood of 
tumor progression from fibrillary to anaplastic variants (Figure 
2C). This recognition of a subclass within grade II astrocytomas 
represents what we believe is a novel finding as well as a prospec-
tive paradigm shift from observation to earlier active therapy in 
the treatment of patients with low-grade gliomas.
Complex interactions between the host immune system and 
malignant tumors are an essential component of how the tumor 
microenvironment is thought to modulate oncologic growth and 
transformation (1, 11). Our findings suggest that high-grade glio-
To further validate that KDR-expressing hematopoi-
etic cells are restricted to the myeloid lineage, we isolated 
KDRGFP+/Lin– hematopoietic cells and performed a colony formation 
assay, which demonstrated that these cells were capable of form-
ing myeloid-derived colonies. Compared with lineage-negative 
WT hematopoietic cells (Lin–WT), which demonstrated the poten-
tial to form all granulocyte-macrophage, granulocyte, and macro-
phage colonies, KDRGFP+/Lin– cells were rarely found to potentiate 
granulocytic colonies (Figure 1E).
To investigate the expression pattern of KDR throughout the 
process of myeloid differentiation, Lin– hematopoietic cells were 
grown in tumor cell line–conditioned (GL261) medium for 1 week. 
Compared with values on day 0, the undifferentiated stem cell 
marker c-Kit was downregulated beginning on day 1 of differen-
tiation, whereas differentiated cell marker CD11b and late-stage 
differentiation marker CD68 were upregulated (Figure 1F). KDR 
expression was maximal on day 1 and day 2 in the early differen-
tiation phase of myeloid lineage cells; however, expression began 
to drop thereafter, suggesting a role for KDR in the early program-
ming of myeloid progenitors toward a protumoral lineage.
Myeloid KDR expression was also assessed in glioma patients. 
As part of this study, peripheral blood samples were prospectively 
collected for 3 years from a cohort of glioma patients diagnosed 
with different tumor grades. We detected significant amounts 
of KDR within permeabilized leukocytes of high-grade glioma 
patients. As shown in Figure 2A, there was a defined CD11b+ pop-
ulation expressing KDR. Within each sample, the ratio of CD11b+ 
KDR+ versus CD11b+ myeloid cells was quantified and plotted 
within each of the WHO-recognized pathological grades. The per-
centage of KDR+ myeloid cells was significantly higher in blood 
samples derived from patients with high-grade gliomas as com-
Figure 2. Elevated KDR expression is 
evident in myeloid cells of high-grade 
glioma patients. (A) Representative flow 
cytometry graphs of CD11b and intracellular 
KDR and isotype control on leukocytes 
of healthy subjects and patients with 
low-grade anaplastic astrocytoma. (B) Dot 
plot of CD11b+KDR+ cell frequency out of 
total CD11b+ cells in patients with different 
stages of glioma. Healthy donors served as 
controls. Grade III/grade IV versus healthy. 
***P < 0.001, 1-way ANOVA. n = 111. G1, 
grade I. (C) Grade II glioma patients were 
subdivided into 2 groups, indicated by the 
red and blue boxes, based on the frequency 
of CD11b+KDR+ cells: KDRhi and KDRlo 
(cut-off, 1.0%). Kaplan-Meier curves for 
progression-free survival over 12 months 
are presented (n = 27). **P < 0.01, log-rank 
test. (D) Immunoblotting of KDR and  
β-actin on different fractions (cytosol 
[Cyto.], membrane [Memb.], input) of leu-
kocytes (LEU) from glioblastoma patients. 
The experiment was conducted 3 times.
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The distribution of KDR on endothelial cells was also shown on 
HUVECs and high-grade murine glioma tissue (Supplemental 
Figure 3, D and E). Immunoblotting of KDR on different cellu-
lar fractions of both myeloid and endothelial cells revealed that 
myeloid-derived KDR was intracellular and intact (Figure 2D).
KDR controls differentiation of protumoral myeloid cells. The obser-
vation that KDR expression was temporally associated with differ-
entiation of tumor-associated myeloid cells prompted us to closely 
examine the role of BM-derived KDR in the immunomodulation 
ma patients harbor greater numbers of infiltrating myeloid cells 
within the tumor tissue and greater numbers of MDSC-like cells 
in the blood than patients with more benign phenotypes (Supple-
mental Figure 2, D and E). In contrast to the typical cell surface 
distribution of KDR in endothelial cells, our results show that KDR 
resides primarily within the cytoplasm of leukocytes (Supplemen-
tal Figure 3, A and B). KDR expression was not detected at signif-
icant levels in nonpermeabilized leukocytes, indicating that KDR 
is mainly intracellular in its localization (Supplemental Figure 3C). 
Figure 3. KO of KDR in BMDCs suppresses spontaneous malignant transformation of RCAS/TVA gliomas. (A) Schematic diagram of experimental design. 
PDGF and Cre genes were transduced to P0–P2 mouse pups on an Ink4a/Arf+/– Ptenfl/fl background. Mice received a lethal dose of irradiation and received 
bone marrow transplant (BMT) at week 2. Tamoxifen was applied to mice at approximately week 5 to induce the ablation of the KDR gene in BMDCs. Tumors 
were monitored by MRI and histological analyses over the process. (B) Kaplan-Meier symptom-free survival curve for RCAS/TVA mice transplanted with 
Rosa26-CreERT2Kdrfl/fl and Rosa26-CreERT2Kdrfl/+ BM cells (BM-KDR KO and BM-KDR CTL, respectively) and RCAS/TVA mice without irradiation/transplan-
tation (without BMT). ****P < 0.0001, log-rank test. (C) At weeks 6, 9, and 12, tumors in each group of mice were assessed and graded based on MRI and 
further confirmation with histology. n = 19–26 for each group. (D) Representative T2-MRI images of intracranial tumors in RCAS/TVA mice transplanted with 
Rosa26-CreERT2Kdrfl/fl and Rosa26-CreERT2Kdrfl/+ BM cells at indicated time points. n = 12. (E) Representative images of H&E and IHC (CD11b, CD31) staining of 
tumor tissue sections from BM-KDR KO and BM-KDR control groups, respectively, at week 9. n = 10. Scale bar: 50 μm.
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diethylenetriamine penta-acetic acid (gadolinium-DTPA) and 
gadolinium-albumin, which closely approximates blood flow (Sup-
plemental Figure 6, A and B). Quantification of MRI on day 18 showed 
that brain tumors in the KDRfl/fl animals were 25% smaller and showed 
an 80% decrease in their contrast enhancement when compared with 
tumors in control animals (Supplemental Figure 6, C and D).
Endothelial and pericyte staining within tumors grown in KDRfl/fl 
mice demonstrated marked differences in blood vessel morphology, 
vasculature size, and pericyte coverage compared with those in the 
control group (Supplemental Figure 7, A and B). Wide-field tumor 
histology in tumors from KDRfl/fl mice demonstrated less hemor-
rhage at the tumor core and a less invasive tumor margin when com-
pared with those in KDRfl/+ mice (Supplemental Figure 7C).
We noted that the microenvironment of xenograft brain tumor 
models may not always accurately reflect the complexity of invasive 
de novo brain tumors and thus approximated this intricacy more 
accurately by challenging findings from the GL261 allograft system 
using the spontaneous RCAS/TVA murine brain tumor model (20). 
In order to examine the role of KDR in BMDCs from RCAS/TVA 
glioma mice, we irradiated and transplanted RCAS/TVA mice at 
week 2 with Rosa26-CreERT2Kdrfl/fl or Rosa26-CreERT2Kdrfl/+ BMDCs 
from littermate donor mice. Tamoxifen was administered to induce 
targeted deletion of the KDR locus specifically within BMDCs 
before host animals first showed evidence of astrocytic tumors at 
approximately week 5. Beginning at week 6, recipient RCAS/TVA 
mice were monitored for tumor progression using weekly MRI 
scans and histological samples from representative sacrificed mice 
of glioma progression. We therefore created a syngeneic astrocytic 
tumor model by orthotopic injection of GL261 cells into the fron-
tal lobes of C57BL/6 mice. These mice harbored BM that had been 
previously transplanted from Rosa26-CreERT2Kdrfl/fl mice with iden-
tical C57BL/6 backgrounds. The efficiency of KDR depletion and 
the subsequent effects upon hematopoiesis within this system were 
then assessed. The KDR allele was deleted in more than 80% of 
BM cells, and a complete blood count was not significantly affected 
by knocking out KDR (Supplemental Figure 4, A–D). At day 3 after 
tumor implantation, tamoxifen was administered to suppress the 
expression of KDR within BMDCs. Tumor growth was monitored 
via daily bioluminescence and weekly MRI scans. Tumor growth was 
significantly suppressed, by approximately 25% (P < 0.05) (Supple-
mental Figure 5A), by selectively knocking out KDR within BMDCs 
(BM-KDR KO, KDRfl/fl) when compared with controls (BM-KDR 
CTL, KDRfl/+). We next assayed for the presence of myeloid cells 
(CD11b) and blood vessels (collagen IV) in GL261 tumors in KDRfl/fl 
mice. These animals had a marked absence of tumor-associated 
myeloid cells within both the tumor core and the tumor periphery 
(Supplemental Figure 5B). While bioluminescence demonstrated 
only subtle differences in tumor burden between the 2 groups, MRI 
revealed a striking difference, particularly in the sequences mea-
suring glioma contrast enhancement. This result suggested a clear 
and direct effect of KDR deficiency within BMDCs upon tumor 
vascularity. GL261 tumors in the control (KDRfl/+) group demon-
strated significantly more enhancement when compared with ani-
mals with KDR-depleted BM (KDRfl/fl), as measured by gadolinium– 
Figure 4. Competitive BMT showed that 
KDR KO in BM cells led to deficiency of the 
differentiation of monocytic cells. Lethal 
dose–irradiated C57BL/6 mice were trans-
planted with Ubc-GFP Rosa26-CreERT2 
Kdrfl/fl and Rosa26-CreERT2KDRfl/+ BM cells, 
and GL261 tumors were implanted after 
BM engraftment. (A) Peripheral white 
blood cells were analyzed on side scatter 
(SSC) and GFP by flow cytometry. The 
GFP+ and GFP– populations were gated for 
further analysis. CD11b versus GFP (B), Ly6C 
versus Ly6G (C), and CD3 versus B220 (D) 
are shown on both GFP+ and GFP– popula-
tions. (E) BM cells were also analyzed on 
side scatter and GFP. (F) Lineage-negative 
cells were gated for analysis of HSCs and 
HPCs by c-Kit versus Sca-1 (G). (H) HPCs 
(Lin–c-Kit+Sca-1–) were further characterized 
by FcγR versus CD34 within both GFP+ and 
GFP– populations. The experiment was 
conducted 5 times.
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were analyzed to confirm anaplasia or malignant transformation 
when scans were suggestive of transformation (Figure 3A). Three 
cohorts of RCAS/TVA mice (i.e., those that received Rosa26- 
CreERT2Kdrfl/fl or control Rosa26-CreERT2Kdrfl/+ BM and those that did 
not undergo irradiation-transplantation) were analyzed based on 
their symptoms associated with late-stage glioma. These symptoms 
included hydrocephalus, lethargy, and weight loss. Kaplan-Meier 
symptom-free survival curves were utilized to demonstrate glioma 
progression in the 3 cohorts. Median symptom-free survival time 
(MSST) was 11 weeks for RCAS/TVA mice transplanted with con-
trol Rosa26-CreERT2Kdrfl/+ BM versus 32 weeks for RCAS/TVA mice 
transplanted with Rosa26-CreERT2Kdrfl/fl BM. For RCAS/TVA mice 
not treated with irradiation or a bone marrow transplant (BMT), 
MSST was 6 weeks (Figure 3B). We compared brain tumors in 
RCAS/TVA mice at weeks 6, 9, and 12 using MRI followed by his-
tological examination (Figure 3C). Knocking out Kdr in BMDCs 
Figure 5. RNA-sequencing reveals gene 
profiles for KDR+ BM cells. (A) The unsu-
pervised principal component analysis of 
significantly altered genes in Lin–c-Kit+ 
Sca-1– from naive mice, Lin–c-Kit+Sca-1– 
KDR-GFP+ cells, and Lin–c-Kit+Sca-1–KDR-
GFP– cells from BM of tumor-bearing mice. 
(B) Lin–c-Kit+Sca-1– cells from naive mice 
(black), Lin–c-Kit+Sca-1– KDR-GFP+ cells 
(red), and Lin–c-Kit+Sca-1–KDR-GFP– cells 
(green) from BM of tumor-bearing mice, 
based on similarity of gene profiles. PC1, 
principal component 1. (C) The candidate 
genes (P < 0.05, >1.5-fold change; Lin–c-
Kit+Sca-1– KDR-GFP+ versus Lin–c-Kit+Sca- 
1–KDR-GFP–) were divided according to the 
subset with the highest expression and 
analyzed for categories with significant 
enrichment (P < 0.05) of categories in 
GO biologic processes using DAVID tools. 
Similar categories were grouped accord-
ingly. The presence of association between 
functions and genes was color highlighted 
(black [negative] versus green [positive]). 
(D) Expression of Id2 in various lineages of 
hematopoietic cells. ***P < 0.001, 1-way 
ANOVA. (E) Expression of ID2 in HPCs 
(CD45–CD34+) from patients with low-grade 
or high-grade gliomas. ***P < 0.001, 1-way 
ANOVA. n = 21. (F) Expression of ID2 in 
CD11b+ blood cells from patients with low-
grade or high-grade gliomas. ***P < 0.001, 
1-way ANOVA. n = 20. Data are shown as 
mean ± SD.
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substantially delayed the malignant transformation of low-grade 
gliomas to higher grade states. By week 9, 60% of RCAS/TVA mice 
transplanted with control Rosa26-CreERT2Kdrfl/+ BM developed high-
grade tumors that had typical malignant features, including robust 
gadolinium enhancement on MRI, pseudopalisading necrosis, and 
microvascular proliferation (Figure 3, D and E). In contrast, tumors 
in 70% of RCAS/TVA mice transplanted with Rosa26-CreERT2Kdrfl/fl 
BM remained in the low-grade stage without signs of malignant 
transformation at week 9 (Figure 3, C–E).
ID2 mediates KDR expression and granulocytic/monocytic cell 
differentiation. Our data demonstrate that KDR contributes to the 
differentiation of proangiogenic myeloid cells and, more impor-
tantly, suggest that these cells play a major role in the modulation 
of gliomas. Within this context, we sought to examine the mecha-
nistic and functional role KDR has in directing the hematopoietic 
fate of KDR-expressing BMDCs in protumorigenic immune cells.
We began by analyzing myeloid cell differentiation either in the 
presence or absence of KDR throughout distinct phases of tumor 
Figure 6. ID2 promotes proangiogenic phenotypes of tumor-associated myeloid cells. (A) Chimeric C57BL/6 mice transplanted with Id2–/– BM cells (Id2+/+ 
BM cells as control) were implanted with luciferase-labeled GL261 tumors intracranially. Tamoxifen was applied at day 3 after implantation. The tumors 
were monitored by bioluminescence. Representative images were taken at day 14. The color bar on the right represents photon intensity. The experiments 
had 2 replicates. The tumor growth curve is based on bioluminescence. n = 10. **P < 0.01, 1-way ANOVA. (B) Flow cytometry analysis of peripheral blood 
cells on CD11b, Ly6C, and Ly6G in Id2+/+ BMT and Id2–/– BMT groups. Quantification of CD11b+ cell frequency out of total white blood cells and of Ly6Chi cell 
frequency out of CD11b+ cells. **P < 0.01, 1-way ANOVA, for each group. n = 7. (C) Tubule formations of HCMEC/D3 (GFP) cocultured with lineage-negative 
Id2+/+, Id2–/–, Id2–/– scrambled sequence (SC) control, or Id2–/– KDR overexpression (OE) HPCs pretreated with TGF-β/GM-CSF. Quantifications of tubule 
lengths in the indicated group. ***P < 0.0001, 1-way ANOVA. n = 6. (D) Growth factor–reduced Matrigel plugs of lineage-negative Id2+/+, Id2–/–, Id2–/– SC CTL, 
or Id2–/– KDR overexpression HPCs pretreated with TGF-β/GM-CSF. Blood vessels (red) were perfused with rhodamine-dextran. Lower panels show magni-
fied views to highlight vascular permeability. Quantifications of based blood vessels density (BVD) in each group. **P < 0.01, 1-way ANOVA. n = 6. Data are 
represented as mean ± SD. Scale bars: 50 μm (D, upper panels); 20 μm (C, D, lower panels).
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ID2 when compared with those from healthy controls and low-
grade glioma patients (P < 0.0001, Figure 5, E and F).
ID2 functions by inhibiting the binding of E proteins to DNA (23). 
To investigate whether ID2 interacted with E proteins to regulate cell 
fate within a myeloid lineage, we analyzed the promoter region plus 
the 5′ UTR of KdR for putative E protein–binding sites, known as E 
boxes. We identified a likely binding site for E2A (Supplemental Fig-
ure 9A) within the upstream promoter region of the Kdr gene. To con-
clusively establish the ID2/E protein/Kdr interaction, we performed 
a ChIP assay using E2A antibody in Id2+/+, Id2 overexpressing, and 
Id2–/– BM cells. As expected, the anti-E2A antibody was able to suc-
cessfully pull down the upstream fragment of Kdr. Overexpression 
of ID2 abolished the binding of E2A to the promoter of the Kdr gene 
(Supplemental Figure 9B); however, the binding capacity of E2A was 
comparable between the Id2+/+ and Id2–/– groups. We hypothesize that 
the basal level of ID2 in WT cells is not high enough to release E2A 
from DNA. Granulocyte-macrophage CSF (GM-CSF) and TGF-β 
induced expression of ID2 and KDR in lineage-negative BM cells 
(Supplemental Figure 9C), similarly to conditioned medium derived 
from GL261 cells, blocking either reversed ID2 or KDR expression. 
These results support the hypothesis that glioma-secreted GM-CSF 
and TGF-β initiate protumoral myeloid cell differentiation, directing 
formation of the KDR+ proangiogenic immune cell population, which 
plays a crucial role in tumor microenvironment and malignant glioma 
transformation. As shown in Supplemental Figure 9D, both total KDR 
and activated KDR were abolished by ID2 deficiency in BMDCs.
ID2/KDR axis directs proangiogenic function of myeloid cells. 
MDSCs are key players in antitumor immunity and angiogenesis in 
several reported malignancies (24–27), and the data from our patient 
cohort and animal models support a central role for these cells in the 
transformation of gliomas. We wanted to further understand the 
contribution of the ID2 signaling axis in regulating the differentia-
tion of protumoral and angiogenic myeloid cells within the context 
of glioma immunomodulation. To begin this analysis, C57BL/6 mice 
that received Id2+/+ or Id2–/– BMTs were orthotopically implanted 
with GL261 tumor cells. GL261 astrocytic tumors grew more slow-
ly in mice with Id2–/– BM compared with those with Id2+/+ BM (P < 
0.01, Figure 6A). Fewer CD11b+ myeloid cells and, remarkably, few-
er CD11b+Ly6C+ cells were recruited to tumors in mice with Id2–/– BM 
compared with those with Id2+/+ BM (P < 0.01, Figure 6B). While the 
endothelial-derived VEGF/KDR signaling axis is well established 
within the regulation of tumor angiogenesis (28), its role in proangio-
genic myeloid differentiation has not been previously established.
To determine candidate downstream targets of ID2 pathway 
signaling, we employed real-time PCR (RT-PCR), utilizing in vitro 
differentiated BMDCs from ID2-competent or ID2-incompetent 
tumor-bearing animals. Among target genes identified in this 
assay (Supplemental Figure 10A), we observed downregulation 
of matrix metallopeptidase 9 (Mmp9), hypoxia inducible factor 
1α (Hif1a), and angiopoietin-2 along with Kdr in Id2–/– BMDCs 
compared with Id2+/+ BMDCs (P < 0.01, Supplemental Figure 
10, B and C). These molecules have been previously described 
as essential components of the tumor microenvironment and 
play an important role in vascular remodeling and angiogenesis 
(29–31). As shown in Supplemental Figure 10D, Mmp9, Hif1a, 
and angiopoietin-2 were upregulated in CD11b+ blood cells of 
mice with high-grade tumors compared with those with low-
progression. BM cells harvested from GFP+ Rosa26-CreERT2Kdrfl/fl 
and GFP– Rosa26-CreERT2Kdrfl/+ mice were mixed in a 1:1 ratio and 
transplanted into recipient mice. These mice were subsequently 
implanted with orthotopic GL261 tumors. Populations of myeloid 
cells, T cells, and B cells residing in the peripheral blood are shown 
in Figure 4, A–D. Populations of HSCs and myeloid progenitors 
residing in BM are shown in Figure 4, E–H. After BM engraftment, 
GFP+ Rosa26-CreERT2Kdrfl/fl BM cells reconstituted 35%–40% of 
hematopoietic cells in both the BM and peripheral blood, where-
as the remainder contained GFP– Rosa26-CreERT2Kdrfl/+ BM cells as 
well as the remaining host hematopoietic cells not eliminated by 
the radiation protocol (Figure 4, A and E). Compared with the con-
trol GFP– population in peripheral blood, the GFP+ population had 
fewer total CD11b+ cells (Figure 4B and Supplemental Figure 8A), 
which contained fewer Ly6C+ cells (Figure 4C and Supplemental 
Figure 8B). There was no significant difference in T cell (CD3+) and 
B cell (B220+) lineages between GFP+ and GFP– populations (Sup-
plemental Figure 8, G and H). Within the BM, the GFP+ population 
had levels of lineage-negative cells and HSCs (Lin–c-Kit+Sca1+) that 
were comparable to those in the GFP– population (Figure 4, F and 
G, and Supplemental Figure 8, C and D). Interestingly, within HPCs 
(Lin–c-Kit+Sca1–), the GFP+ population had significantly more com-
mon myeloid progenitor cells (Lin–c-Kit+Sca1–FcγR–CD34+) and sig-
nificantly fewer granulocytic/monocytic myeloid progenitor cells 
(Lin–c-Kit+Sca1–FcγR+CD34+) in comparison with the GFP– popula-
tion (Figure 4H and Supplemental Figure 8, E and F). This indicates 
that by selectively knocking out Kdr in BMDCs, the differentiation 
of common myeloid progenitor cells into granulocytic/monocytic 
myeloid progenitor cells was suppressed. We performed in vitro col-
ony formation assays using Kdr+/– and Kdr–/– BM cells and observed 
significantly fewer granulocytic macrophage and macrophage colo-
nies forming from Kdr–/– BM cells (Supplemental Figure 8I).
To further define the KDR signaling network responsible for 
directing differentiation down a myeloid lineage, we performed 
gene-expression profiling of KDR-expressing (KDRGFP+) HPCs 
(Lin–c-Kit+) using mRNA sequencing. Differentially expressed 
genes from KDRGFP+ versus KDRGFP– HPCs were also clustered 
and displayed using a heat map (Figure 5A), and similar cate-
gories were grouped accordingly (Figure 5B). Candidate genes 
(P < 0.001, >2-fold change) were divided according to subsets with 
the highest expression, and categories with significant enrich-
ment (P < 0.001) in Gene Ontology (GO) were derived using 
DAVID tools (22) (Figure 5C). Id2 was identified as a markedly 
upregulated gene in KDRGFP+ HPCs. As a well-defined transcrip-
tional regulator controlling the timing of cell-fate determination 
and the differentiation of stem and progenitor cells, ID2 was a 
strong candidate for an upstream modulator of myeloid differ-
entiation through KDR signaling. To validate the upregulation of 
Id2 in HPCs, we performed real-time PCR on KDRGFP+ HPCs and 
Ly6C+/Ly6G+ myeloid cells from tumor-bearing or naive mice. 
KDRGFP+ HPCs from tumor-bearing mice had higher Id2 levels 
than did KDRGFP– HPCs and HPCs from naive mice (Figure 5D). 
The expression of Id2 was generally lower in myeloid cells than in 
HPCs. We also examined the expression of ID2 in glioma patients. 
HPCs and CD11b+ cells were isolated from both healthy controls 
and low- and high-grade glioma patients. HPCs and CD11b+ cells 
from high-grade glioma patients had significantly higher levels of 
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Previous research has demonstrated that KDR can also be found 
in the cytosol and nucleus in addition to its known localization on the 
cell membrane. KDR translocates to the inside of cells upon VEGF 
stimulation in a process that requires phosphorylation of the recep-
tor (28, 38, 39). It has become clear that endocytosis and intracel-
lular trafficking of KDR is key to the activation of VEGFR signaling 
(40–42). In connection with their proangiogenic functions, tumor- 
associated myeloid cells and myeloid progenitors serve as a major 
source of VEGF in many types of malignant lesions (4, 43). Given 
this information, we hypothesize that high concentrations of VEGF 
within myeloid cells restrain its receptor, KDR, from being localized 
on the cell surface. Instead, the majority of KDR remains within 
intracellular compartments of myeloid cells in an activated state.
Recent studies have demonstrated that malignant lesions 
polarize macrophages and neutrophils within the tumor micro-
environment and redirect them toward tumor-promoting pheno-
types (24, 44, 45). Prior to arriving at and populating tumor tissues, 
BMDCs receive soluble tumor-directed signaling (7, 18, 46). As they 
progress, malignancies evade immune surveillance by promoting 
immunosuppressive cells and suppressing antigen-presenting cell 
functions (26, 47). Primary tumors also prime BMDCs to facilitate 
neovascularization, allowing for exponential growth. Infiltration of 
several types of proangiogenic BMDCs, such as Tie-2+–expressing 
monocytes and c-Met+ hematopoietic progenitors, increases as pri-
mary tumors progress (7, 46). Since these proangiogenic myeloid 
cells appear to have a direct role within malignant transformation, 
they may serve as prognostic markers of early transformation in 
cancer patients with low-grade gliomas (48–50). For the majority 
of solid tumors, staging and prognosis are based upon direct tumor 
biopsies, which lack meaningful information about the tumor 
microenvironment (50). After surgery, most patients receive radi-
ation therapy, chemotherapy, and/or targeted therapy, from which 
the tumor microenvironment may be affected dynamically and 
extensively. Considering the high incidence of tumor transforma-
tion, progression, and recurrence within patients with low-grade 
gliomas, it is important to consider real-time monitoring approach-
es in addition to MRI imaging in glioma patients.
Inhibitors of DNA-binding proteins have been shown to play 
important roles in mediating hematopoietic differentiation in 
physiological settings (23, 51). It has been shown, for example, that 
ID2 serves as a suppressor of lymphoid and B cell development 
(52, 53); however, the role of ID2 in myeloid differentiation within 
malignancies has not been as well described in the literature (6, 7). 
In this study, we have demonstrated that E2A, the binding partner 
of ID2 (23, 53), directly binds the Kdr promoter region, illuminat-
ing a crucial link between ID2 and myeloid differentiation. We 
have shown that enhanced ID2/KDR signaling, induced by pri-
mary glioma, promotes the differentiation of MDSCs, particularly 
along a monocytic lineage. These results have expanded upon the 
previous understanding of KDR as simply an endothelial activator 
and elucidated a role for KDR as a molecular regulator responsible 
for directing proangiogenic myeloid cell differentiation. This sug-
gests that ID2 may play an important part in protumoral MDSC 
formation. Targeting the ID2/KDR axis within myeloid-derived 
cells may serve as an extratumoral therapeutic approach for sup-
pressing glioma progression through immunomodulation of the 
tumor microenvironment.
grade tumors. These proangiogenic factors are also significantly 
higher in KDR+ myeloid cells than those in KDR– myeloid cells 
(Supplemental Figure 10E). To further define the proangiogenic 
functions of the ID2/KDR pathway within our identified myeloid 
cell population, we performed in vitro tube-forming assays under 
different conditions. We coincubated GFP-brain endothelial cells 
(HCMEC) with previously in vitro–differentiated Id2+/+ and Id2–/– 
BMDCs. In order to determine whether KDR overexpression 
would have a discernible effect on myeloid cells in the absence 
of ID2, Id2–/– BMDCs were also transduced by lentivirus over-
expressing either a scrambled control or the WT Kdr gene. ID2- 
expressing BMDCs strikingly promoted tube formation; howev-
er, ID2-deficient BMDCs were unable to support the formation 
of endothelial tubules. KDR overexpression allowed BMDCs to 
regain their protubule-promoting capability (P < 0.0001, Figure 
6C). In parallel, we performed an in vivo Matrigel plug assay uti-
lizing the same BMDC conditions. Id2+/+ BMDCs demonstrated 
potent induction of neovascularization in Matrigel plugs (P < 0.01, 
Figure 6D), whereas loss of ID2 compromised the proangiogenic 
functions of BMDCs. Once again, overexpression of KDR rescued 
the proangiogenic phenotype of BMDCs. Interestingly, while the 
overexpression of KDR in Id2–/– BMDCs showed enhanced pro-
angiogenic capability, the blood vessels induced by Id2–/– BMDCs 
with overexpression of KDR were noticeably leakier than were 
those induced by WT BMDCs, as was evidenced by permeability 
of dextran. While we demonstrated that overexpression of KDR in 
BMDCs convincingly rescues the angiogenic deficiency induced 
by loss of the Id2 gene, the histoarchitecture remains imperfect 
and warrants further investigation.
Discussion
KDR has been previously described as a marker for endotheli-
al progenitor cells and has been considered a specific marker for 
endothelial progenitors within BMDCs (1, 18, 32–34). Recent-
ly, however, KDR was identified in plasmacytoid dendritic cells 
during innate immune responses, suggesting additional roles 
for KDR in physiological processes (19). Using multiple compli-
mentary approaches, we have demonstrated the expression and 
unique role of KDR in myeloid cells. Despite its lower expression 
levels in BMDCs compared with endothelial cells, KDR in BMDCs 
controls the differentiation of HPCs into proangiogenic myeloid 
cells, thereby directly affecting the composition of the tumor 
microenvironment. The majority of KDR-expressing BMDCs are 
CD11b+Gr-1+ (Ly6C+Ly6G+) cells, also known as MDSCs (6, 35). 
Besides the canonical immunosuppressive role of MDSCs, we 
observed distinct phenotypes on tumor-associated vascular devel-
opment when KDR was selectively deleted from BM cell popula-
tions. Within the tumor microenvironment, macrophages and neu-
trophils have been shown to have robust proangiogenic capabilities 
in multiple disease states (4, 24, 36). Until now, the mechanisms 
by which MDSCs differentiate into tumor-associated macrophages 
or neutrophils have not been convincingly demonstrated (26, 37); 
however, in our study, elimination of KDR-expressing BMDCs 
yielded fewer myeloid cells and normalized blood vessels with-
in the tumor microenvironments. Our results suggest that KDR- 
mediated proangiogenic myeloid cells are crucial for malignant 
progression in fibrillary astrocytomas.
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mm below the surface of the skull using a 1 μl Hamilton syringe). Mice 
were euthanized when they presented with neurological symptoms or 
substantial weight loss. Mice were examined and weighed daily. Bio-
luminesence and MRI were performed to monitor the progression of 
tumors. Bioluminesence was performed under the IVIS-100 (Xeno-
gen) system, and images were acquired and analyzed by Living Image 
(Caliper). High-resolution MRI images were acquired on a 7.0-T ani-
mal scanner system (Bruker Biospin). 200 μl of 40 mM Gd-DTPA or 
Gd-albumin was injected by tail vein to measure brain tumor contrast 
enhancement. During imaging, animals were under isoflurane anes-
thesia and monitored for respiration and heart rate; the temperature 
was kept at 37°C. Images were analyzed by an OsiriX DICOM viewer.
Tamoxifen administration. To induce KDR gene ablation, at day 3 
after injection, mice with intracranially implanted tumor cells were 
treated with tamoxifen (20 mg/kg intraperitoneally) for 6 days, 
interrupted for 3 days after the third dose. After 3 days of respite, 
the fourth dose was reinstituted for an additional 3 days, resulting in 
Rosa26-CreERT2Kdrflox/flox (KDRfl/fl) mice that were deficient in KDR at 
both alleles. The control animals were Rosa26-CreERT2Kdrfl/+ mice.
BMT and competitive BMT. Recipient mice were lethally irradiated 
with a single dose of 9.5 Gy applied to their whole bodies with their heads 
lead shielded; 24 hours after irradiation, 5 × 106 total BM cells were inject-
ed by tail vein. The BM of donor mice was harvested by flushing femurs 
and tibias with cold sterile EDTA/PBS. Engraftment was confirmed by 
complete blood count using a Hemavet 850 blood cell counter (Drew Sci-
entific) and flow cytometry to ensure adequate hematopoiesis. For com-
petitive BMT, we mixed donor BM cells from Ubc-GFP Rosa26-CreERT2 
Kdrfl/fl mice and Rosa26-CreERT2Kdr fl/+ mice at a 1:1 ratio and injected 5 
× 106 total cells into recipient mice; 3 days after tumor implantation, we 
treated mice with tamoxifen to induce the deletion of the Kdr allele.
IHC and immunostaining. Antibodies utilized for IHC and 
immunostaining included the following: anti-mouse CD11b (clone: 
M1/70, eBioscience), anti-human CD11b (catalog ab52478, Abcam), 
anti-VEGFR2 (KDR) (catalog 9698, Cell Signaling), anti–collagen IV 
(catalog ab19808, Abcam), anti-CD31 (clone: MEC13.3, BD Bioscienc-
es), anti–von Willebrand factor (catalog AB7356, Millipore); and anti-
Ki67 (catalog ab15580, Abcam).
Secondary antibodies utilized included the following: FITC- and 
Cy3-conjugated donkey anti-goat/ anti-rabbit/anti-rat (catalog 711-095-
152; 711-165-152; 712-095-150; 712-165-150, Jackson ImmunoResearch); 
Alexa Fluor 488– and Alexa Fluor 555–conjugated donkey anti-mouse 
(catalog A-21202; A-31570; Invitrogen); and biotinylated goat anti-rabbit 
(catalog BA-1000, Vector).
Cell preparation and flow cytometry (intracellular staining). Hema-
topoietic cells isolated from buffy coats were subjected to trypan blue 
staining or live/dead cell staining (Fixable Dead Cell Stain Kits, Invit-
rogen). Cells were then fixed in 0.05% formaldehyde for 10 to 15 min-
utes followed by disruption of membrane by detergent Tween 20 at 
0.5% v/v in PBS for 15 minutes. Cells were washed by PBS (containing 
0.1% Triton X-100 or other permeabilizing detergent) and centrifuged 
at 300 g for 5 minutes; supernatant was discarded. Cells were resus-
pended in the volume remaining. Antibodies were given according to 
manufacturer directions. Antibodies were prepared in permeabiliza-
tion buffer to ensure that cells remained permeable. Cells were count-
ed, and 1 × 106 cells from each sample were subject to flow analysis 
using FACSCalibur (BD). All cells were stained at 4°C in PBS with 
2% FCS. The following antibodies were used for staining: APC anti- 
Methods
Cell lines and mouse lines. C57BL/6, Rosa26-CreERT2, Id2GFP–knockin, and Ubc-
GFP mice were obtained from The Jackson Laboratory. Kdr (Vegfr2)fl/fl, 
KDRGFP–knockin, Rosa26-CreERT2, Kdrfl/fl (Vegfr2fl/fl), and Ubc-GFP mice on 
a C57BL/6 background were obtained from Shahin Rafii. Littermate 
controls were used in all animal experiments. Rosa26-CreERT2 mice were 
crossed with Kdrfl/fl mice to generate Rosa26-CreERT2Kdrfl/fl mice. The lit-
termates of Rosa26-CreERT2Kdrfl/+ mice served as controls. GL261 cells 
were obtained from David Zagzag (Department of Pathology, New York 
University, New York, New York, USA). HCMEC cells were obtained from 
Babette Weksler (Department of Medicine, Weill Cornell Medicine).
RCAS/TVA glioma model and symptom-free survival analysis. 
RCAS-hPDGFb-HA-SV40 containing human PDGFb with partially 
deleted 59UTR, RCAS-hPDGFb-HA, and RCAS-Cre vectors were 
transfected into DF-1 chicken cells (ATCC). DF-1 cells transfected with 
RCAS-PSG were cultured in 10% FBS-DMEM media under standard 
conditions. For tumor induction, transfected DF-1 cells were tryp-
sinized, centrifuged, and injected into the brain parenchyma of n-tva 
mice on a heterozygous Ink4a/Arf+/–Ptenfl/fl background (obtained 
from Eric Holland) at P0–P2. The mice transgenically expressed the 
RCAS-binding tva receptor after the nestin promoter. For BMT study, 
the RCAS/TVA mice at week 2 were subject to 9.5 Gy irradiation with 
their heads shielded and transplantation of donor BM cells through 
retroorbital injection as well as the procedures described in the BMT 
section. Upon appearance of brain tumor symptoms (e.g., poor groom-
ing, lethargy, macrocephaly, hydrocephaly, hemiparesis, substantial 
weight loss), mice were anesthetized by intraperitoneal injection of 
1 mg/kg Nembutal solution or a ketamine (150 mg/kg)/xylazine (15 
mg/kg) cocktail and underwent transcardiac perfusion with 10 ml ice-
cold heparin in normal saline, followed by 10 ml ice-cold 4% parafor-
maldehyde. Brain tissue was extracted and postfixed for 30 minutes in 
ice-cold 4% paraformaldehyde and transferred to 30% sucrose at 4°C 
for cryoprotection. For a subset of animals sacrificed using CO2, brain 
tissue was extracted and fixed for 3 days in 4% paraformaldehyde and 
subsequently processed using standard paraffin embedding and pro-
cessing. Kaplan-Meier curves for symptom-free survival were made 
using Prism software and analyzed with a standard log-rank test. The 
end-point was defined as the time mice had developed symptoms such 
as hydrocephaly and lethargy.
Genotyping. Genotyping methods, primer sequences, and PCR 
conditions were as follows: Rosa26-CreERT2: WT forward, 5′-AAAGTC-
GCTCTGAGTTGTTAT-3′, WT reverse, 5′-GGAGCGGGAGAAATG-
GATATG-3′, mutant reverse, 5′-CCTGATCCTGGCAATTTCG-3′, 94 × 
30 seconds, 65 × 30 seconds, 72 × 60 seconds, 35 cycles, WT band 650 
bp, mutant band 825; Kdrfl/fl: forward, 5′-CCACAGAACAACTCAGG-
GCTA-3′, reverse, 5′-GGGAGCAAAGTCTCTGGAAA-3′, 94 × 30 sec-
onds, 60 × 30 seconds, 72 × 60 seconds, 35 cycles, WT band 185 bp, 
with LoxP site 231 bp; Id2 GFP–Knockin: primer 12341, 5′-CTTCCTCCTAC-
GAGCAGCAT-3′, primer 12342, 5′-CTCACCTGCAAGGACAG-
GAT-3′, primer 12343, 5′-GCTCCTGGACAGGAATCAAG-3′, 94 × 30 
seconds, 59 × 60 seconds, 72 × 60 seconds, 35 cycles, WT band 371 bp, 
mutant band 750 bp; GFP: forward, 5′-CTGCTGCCCGACAACCA-3′, 
reverse, 5′-TCCAGCAGGACCATGTGATC-3′.
Intracranial injections and MRI/bioluminescence imaging. Luciferase- 
labeled GL261 cells (1 × 105) were stereotactically inoculated into the 
right hemispheres of 8-week-old mouse brains (1.5 mm posterior to the 
bregma and 1.5 mm to the right of the sagittal suture to a depth of 2.5 
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GTGTC-3′, 5′-AGAGATGAATTCTGCGCCAT-3′; murine c-Kit: 
5′-AGAAGGAAGCGTGACTCGTT-3′, 5′-TTGAACTGTCACAG-
GAAGGC-3′; murine β-actin: 5′-CGGTTGGCCTTAGGGTTCA-3′, 
5′-GTGGGCCGCTCTAGGCACCA-3′.
CFU assay. BM cells (1 × 104) from each group of mice were har-
vested and cultured in 2 wells of a 24-well culture plate supplemented 
with standard methylcellulose medium containing 10 ng/ml murine 
IL-3, 10 ng/ml human IL-6, and 50 ng/ml murine SCF (StemCell Tech-
nologies). Granulocyte, macrophage, and granulocyte-macrophage 
CFU were counted after 7 days of culture.
Endothelial tubule formation. GFP-labeled HCMEC/D3 (5 × 104/
well) cells were seeded on 24-well plates coated by Matrigel with 
reduced growth factors (200 μl/well, BD Biosciences) and incubated 
for 6 hours followed by coculture with BMDCs. Spatial organization 
and sprout configuration were assessed after 12 hours using in situ flu-
orescence imaging. Cumulative sprout lengths of tubules represented 
by area of GFP+ field were quantitatively analyzed using ImageJ (NIH).
Matrigel plugs. Growth factors were thawed and Matrigel (BD Bio-
sciences) was reduced on ice overnight at 4°C. The Matrigel was mixed 
with specified BMDCs on a vortex and placed on ice. A syringe with 
each solution was used to inject 0.5 or 1 ml subcutaneously into the ven-
tral area of each mouse. After 10 days, mice were injected with 100 μl 
(10 mg/ml) 70-kD DsRed-dextran by tail vein. Ten minutes later, ani-
mals were sacrificed, followed by 4% paraformaldehyde perfusion, and 
plugs removed. Plugs appeared as bumps on the ventral side of the ani-
mal. Whole plugs were placed in gradients of methanol from 25% to 
100% and then into benzyl alcohol benzyl benzoate (Sigma-Aldrich) at 
a 1:2 ratio. Plugs were then mounted for fluorescent imaging.
Zymography. Supernatant was harvested from specified cells, con-
centrated with 10-kD centrifugal filter columns (Millipore), and loaded 
without a reducing reagent to 12% gelatin gel (Invitrogen). Zymogra-
phy development was done with Novex precast zymography buffers 
(Invitrogen) by following the manufacturer’s instructions. Following 
electrophoresis, the gel was incubated with 100 ml of renaturing buffer 
under gentle agitation for 30 minutes. Renaturing buffer was removed, 
100 ml of developing buffer was added, and the gel was incubated 
under agitation for 30 minutes. Developing buffer was then removed 
and another 100 ml of developing buffer was added. The zymogram 
was then placed in the humidified incubator set to 37°C and incubated 
overnight. Developing buffer was removed and replaced with 100 ml 
of deionized water. The zymogram was washed 3 times under gentle 
agitation for 5 minutes, stained with 0.5% Coomassie G250 in 30% 
ethanol and 10% acetic acid for 30 minutes, and then destained in 30% 
ethanol/10% acetic acid. Destaining was quenched by transferring the 
gel to 2% acetic acid when the clear bands were observed.
CHIP assay. BM progenitor cells were collected and cultured as 
described above. Protein-DNA complexes were crosslinked by incu-
bating the cells with 37% formaldehyde diluted to a 1% final con-
centration and incubating with cells on a rocking or shaking device 
for 15 minutes at room temperature. Formaldehyde was quenched 
by adding 1 M glycine diluted to a final concentration of 125 mM. 
Cells were rocked for 5 minutes at room temperature and pelleted; 
medium was removed. Protease inhibitors were added to the Lysis 
buffer (10 μg/ml leupeptin, 10 μg/ml aprotinin, and 1 mM PMSF). 
The cell pellet was resuspended in 500 μl of lysis buffer per 5 × 106 
cells and incubated on ice for 10 minutes. Samples were sonicated 
to shear chromatin to an average length of about 1 kb. 500 μl of each 
human KDR/isotype control, PEcy7-Ly6C, PE-Ly6G, PE-CD33, Bio-
tin Mouse Lineage Panel (559971, BD Biosciences — Pharmingen), 
FITC/eF450 CD45 (clone 30-F11), PE/APC–c-Kit (clone 2B8), PE/
PEcy7–Sca-1 (clone D7), FITC/eF450-CD11b (clone M1/70), PE–Gr-1 
(clone RB6-8C5), PEcy7–HLA-DR (clone LN3), AF-700/APC-CD16 
(clone CB16), APC/PEcy7-CD14 (clone 61D3), eF5.5-FcrRII (AT130-
2), Pacific Blue/FITC-streptavidin (11-4317,eBioscience), and Pacific 
Blue/Mouse Lineage Panel (133310, BioLegend). Data were analyzed 
by FlowJo software. Analysis was done within single cell gate after the 
exclusion of debris and dead cells.
RNA sequencing analysis. CD11b+Gr-1+ KDR-GFP+ myeloid cells 
were sorted from peripheral blood, and c-Kit+Sca-1–KDR-GFP+ pro-
genitor cells were sorted from BM cells by FACS (BD) directly into cell 
lysis buffer provided in the RNeasy Micro Kit (QIAGEN). Total RNA 
BM progenitor cells in each group were extracted with an RNeasy 
Microkit followed by cDNA amplification; 3 or 4 independent samples 
from each group were subjected to RNA-sequencing (Illumina HiSeq 
2000). Gene expression data were analyzed using the Limma package 
in R/Bioconductor software, using a P value of less than 0.001 and 
fold change greater than 2. By unsupervised analysis, these samples 
were clustered based on their expression profiles. Z scores were used 
in the cluster analysis. All original microarray data were deposited in 
the NCBI’s Gene Expression Omnibus (GEO GSE94271).
In vitro culture of HPCs. Whole BM was harvested from 7- to 
10-week-old donor mice (C57BL/6 or Kdr/Id2 deficient mice as speci-
fied in each experiment). Briefly, femur and tibia were removed and the 
BM was harvested by flushing it with cold RPMI medium containing 
1% penicillin/streptomycin using a syringe equipped with a 25-gauge 
needle. Uncommitted BM progenitors, highly enriched in HSCs, were 
negatively selected using either the Lineage Cell Depletion Kit for 
mouse (Miltenyi Biotec) or the Hematopoietic Progenitor Enrichment 
Kit (StemCell Technologies) following the manufacturer’s protocols. 
The lineage− selected cells (Lin− BM cells) were placed in culture at 1 × 
106 cells/ml in StemSpan medium (StemCell Technologies) containing 
1% penicillin/streptomycin, 100 ng/ml murine stem cell factor (SCF), 
100 ng/ml human Fms-like tyrosine kinase 3, 100 ng/ml human IL-11, 
and 20 ng/ml murine IL-3. All cytokines were purchased from Pepro-
Tech. The Lin− BM cells were transduced with the appropriate lentivi-
ral particles at an MOI of 10. At 18 to 24 hours after transduction, the 
transduced Lin− BM cells were harvested, washed, and resuspended in 
RPMI medium containing 1% penicillin/streptomycin at 2.5 × 106 cells/
ml for subsequent studies. For treatment of tumor cells, conditioned 
medium, serum-free RPMI that had been conditioned by GL261 tumor 
cells for 24 hours, was added at a 1:1 ratio into Lin– BM cells. For treat-
ment of cytokines or antibodies, 1.5 ng/ml TGF-β1, 10 ng/ml GM-CSF, 
or 10 μg/ml TGF-β1 neutralized antibodies were used.
RT-PCR. RNA from the sorted or cultured cells was extracted 
using the RNeasy kit (QIAGEN) and reverse transcribed using Super-
script III reverse transcriptase (Invitrogen). Quantitative PCR (QPCR) 
was performed on a 7500 Fast Real Time PCR System (Applied Bio-
systems) with SYBR green (Life Technologies). Probes were as follows: 
murine Kdr: 5′-CCATTGGAGGAACCAGAAGT-3′, 5′-CTCTTCT-
GATGCAAGGACCA-3′; human ID2: 5′-TCAGCCTGCATCACCAGA-
GA-3′, 5′-CTGCAAGGACAGGATGCTGATA-3′; murine Id2: 5′-AAAA-
CAGCCTGTCGGACCAC-3′, 5′-CTGGGCACCAGTTCCTTGAG-3′; 
murine Cd11b: 5′-CTGAGAAATGACGGTGAGGA-3′, 5′-CAGCAG-
GCTTTACAAACCAA-3′; murine CD68: 5′-GCGGTGGAATACAAT-
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t tests and 1-way ANOVA, followed by a post-hoc test for comparison 
of multiple groups. Significance was determined as a P value of less 
than 0.05.
Study approval. All animal experiments were performed accord-
ing to the guidelines set forth by the Institutional Animal Care 
and Use Committee at Weill Cornell Medicine. Human peripher-
al blood samples were obtained from subjects with grades I, II, III, 
and IV gliomas at Weill Cornell Medical College and were histo-
logically confirmed as gliomas. Subjects with grade II gliomas were 
followed up over 12 months. Tumor progression was determined by 
either histology or radiography. All individuals provided informed 
consent for blood donation according to a protocol approved by the 
institutional review board.
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sample was transferred to a 1.5-ml microcentrifuge tube and centri-
fuged for 10 minutes using a refrigerated ultracentrifuge at 12,000 
g. Supernatant was collected in a clean tube and the pellet discard-
ed. Supernatant was diluted by adding 1 ml of dilution buffer and 
5 μg of the E2A antibody (Santa Cruz Biotechnology Inc., sc-763) 
or normal IgG to the samples and incubated overnight at 4°C on a 
rotating device. Secondary biotinylated antibody was added at 5 μg 
and incubated for 1 hour at 4°C on a rotating device. We added 100 
μl of streptavidin magnetic beads to the samples and rotated for 30 
minutes at 4°C. The beads were collected by leaving the tube in the 
magnet for 2 minutes and were washed with prechilled wash buf-
fers. After the last wash, 100 μl of chelating resin solution was add-
ed directly to the beads and pipetted up and down for about 10 sec-
onds. The sample was boiled for 10 minutes using a heat block or a 
temperature-controlled water bath and microcentrifuged at 12,000 
g for 1 minute at room temperature before transferring the super-
natant to a clean microcentrifuge tube. The DNA preparation was 
cleaned and concentrated using a DNA purification kit (QIAGEN) 
and resuspended in 30 μl of deionized or distilled water. 2 μl of the 
DNA sample was used in the real-time PCR reactions.
The probes for KDR promoter region were as follows: sense: 
CCTGGTTTGCCACCTGCTTCTG; antisense, TGTAACATGGT-
GCTTTTCTTT.
Statistics. All data are given as mean ± SD or ± SEM. n was used 
to show the number of biological replicates within figure legends. 
(a) For quantification of IHC, n represents the number of biological 
samples within each group. First, we randomly selected 5 slides from 
each sample/mouse. Nine fields from each slide were counted, and 
an average number per field was used to represent each slide. Then 
the mean of values from 5 slides was used to represent each sample/
mouse and graphs were generated based on n independent samples/
mouse. Two independent observers blindly measured or counted to 
determine intra- and interobserver variability. (b) n in animal experi-
ments represents the number of mice in each group. (c) n in RT-PCR 
and cell count experiments represents the number of independent 
wells of treatment per condition, each of which represents the mean 
value from 3 experimental wells. In “Endothelial tubule formation,” 
the value of each well is the mean of cell counts of six 100× fields ran-
domly chosen within a well, and n is the number of independent wells 
of treatment per condition. Differences between the mean parameter 
values derived from 2 groups were compared using 2-tailed Student’s 
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